Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Shareholder Meeting (November 2022)
42 slides from Optiscan Imaging's shareholder meeting presentation, Nov 24, 2022
Slide 1: Annual General Meeting November 2022
Annual General Meeting November 2022
Slide 2: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 24 November 2022. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor m
Slide 3: Notice
Notice Not an offer or financial product advice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure doc
Slide 4: Chairman's Address
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Chairman’s Address Mr Robert Cooke, Non-Executive Chairman 4
Slide 5: Chairman's Address
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Chairman’s Address Good morning shareholders and welcome to the Optiscan 2022 Annual General Meeting. The past year has seen a number of changes to the Company with the appointment of Professor Camile Farah as Managing Director in December 2021, and the ap
Slide 6: Optiscan Board: Experienced Leadership
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Optiscan Board: Experienced Leadership Dr Camile Farah Robert Cooke Sean Gardiner Karen Borg Ron Song CEO & MD Board Chair Non-Executive Director Non-Executive Director Non-Executive Director • Proven track record • Managing • Medtech leader • Track record
Slide 7: Managing Director's Report
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Managing Director’s Report Dr Camile Farah, CEO & Managing Director 7
Slide 8: Welcome to Country
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Welcome to Country I begin today by acknowledging the Traditional Owners of the land on which we meet, the Wurundjeri and the Boon Wurrung people of the Kulin Nation, and pay my respects to their Elders past, present and emerging. 8
Slide 9: Acknowledgement: Vale Peter Delaney
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Acknowledgement Vale Peter Delaney As one of the founders of Optiscan, Peter served in senior management roles including Chief Executive Officer, Chief Technology Officer, and board member for over 25 years. Peter's wisdom, knowledge, and deep understandin
Slide 10: Optiscan: Imaging in the palm of your hand
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Optiscan: Imaging in the palm of your hand Global leader in confocal cellular level imaging for medical, translational and pre-clinical applications Est. 1994, ASX listed medical device company Unique, patented cutting edge technology: Sub-cellular, 3D l
Slide 11: Technology: Excellent Correlation to Conventional Histopathology
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Technology: Excellent Correlation to Conventional Histopathology Cancer vs Normal Correlation with Histopathology Oesophagus Colon Breast Endometrium Mesothelioma Pituitary Adenoma OPTISCAN NORMAL HISTOPATHOLOGY CANCER 11
Slide 12: Improving Cancer Outcomes: A Global Challenge
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Improving Cancer Outcomes: A Global Challenge 1 2 3 4 High, growing Cancer treatment Frozen section Traditional cancer rates are a lacks accuracy and procedure is time- Challenge histopathology is not huge burden on results in high consuming, costly instan
Slide 13: Optiscan: Value Proposition
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Optiscan: Value Proposition Patients & Clinicians & Insurers & Advocates Hospital Executives Healthcare Providers High resolution, real-time Non-invasive diagnostic imaging Established CPT reimbursement digital microscopic imaging and better surgical outco
Slide 14: Optiscan: Value Proposition
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Optiscan: Value Proposition Novel imaging solutions for contemporary clinical practice • Digital microscopic imaging and diagnosis on-the-fly • Speed of image delivery and ability to share images is crucial to immediate, informed decision making • Reduces
Slide 15: Optiscan: Value Proposition
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Optiscan: Value Proposition Digital imaging solutions for operating rooms of the future • Real-time feedback in the Operating Room • Empowers precision medicine – ultimate outcome in cancer treatment is removal of diseased tissue while preserving normal st
Slide 16: Optiscan: Value Proposition
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Optiscan: Value Proposition Opportunity to establish new standard of precision healthcare Real time feedback Visually monitor over time Track disease treatment impact Pathologist / Clinician digital collaboration Unlimited sampling Workflow eff
Slide 17: Product Range: Differentiated Clinical & Research Devices
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Product Range: Differentiated Clinical & Research Devices InVivage® Clinical Device ViewnVivo® Research Device FEATURES FEATURES • Push-button handpiece for easy operator use • Miniaturised hand-held probe with 4 mm diameter tip • Advanced software user in
Slide 18: Key Achievements in 2022
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Key Achievements in 2022 On a growth trajectory, in preparation for launch into overseas markets Submission of FDA 510(k) application for InVivage® approval in US • Submitted application for premarket clearance in late August 2022 Completion of oral cancer
Slide 19: FY22 Financial Highlights
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE FY22 Financial Highlights On a growth trajectory, in preparation for launch into overseas markets FY22 Revenues from ordinary activities up ~14% on FY21 to $1.01m • Pre-clinical system, ViewnVivo®, had first few sales recorded for Australia • Convivo – Car
Slide 20: Selected 2022 publications using Optiscan technology
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Selected 2022 publications using Optiscan technology Neurology Life Sciences & Clinical Ligand-switchable nanoparticles resembling viral surface for Real-time intraoperative surgical sequential drug delivery and telepathology using confocal laser improved
Slide 21: Strategic Pillars
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Strategic Pillars
Slide 22: New strategic pillars
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE New strategic pillars Building momentum Operational Business strategy & Brand Technology Financial excellence implementation recognition commercialisation sustainability 22
Slide 23: Internal positioning for growth
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Internal positioning for growth New strategy Implementation • New business strategy and sales/marketing plans • Refurbishments of existing spaces Enhanced via support from Australian • Leasing of additional space for production Government Entrepreneurs’
Slide 24: Our Mission & Vision
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Our Mission & Vision OUR MISSION To enable informed decisions for optimised global healthcare. OUR VISION To be a global leader in digital healthcare solutions. 24
Slide 25: Our Values
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Our Values Bold and courageous Continuous improvement Empower each other Customer focused Commercial mind and warm heart Responsible and accountable We have a strong purpose of transforming people’s lives through earlier and less invasive diagnosis and tre
Slide 26: Sales strategy update – Life Sciences
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Sales strategy update – Life Sciences Fresh approach • Dedicated distributor partners – South Korea, China, Taiwan Appointment of new China distributor Implementation of new training programs with positive feedback Distributors engaged for commercial
Slide 27: Expanded marketing capabilities - InVivage
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Expanded marketing capabilities - InVivage® Increased international engagement and proximity to customers and industry influencers 2022 Conferences 2022 Trade fairs Meeting Exposure Meeting Exposure Leading oral medicine physicians Global executives and in
Slide 28: Expanded marketing capabilities - Optiscan.com
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Expanded marketing capabilities - Optiscan.com • New website includes value proposition, articulation of solutions in clinical and life sciences • Website embeds new lead capture mechanism linking to new CRM system • Live, dynamic company updates • Incorpo
Slide 29: Expanded marketing capabilities
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Expanded marketing capabilities Brand identity • Circle as focal element representing precision and single optical fibre, key features of our technology • New byline Immediate Informed Decisions Media coverage • Australasian College of Health Services, Hea
Slide 30: Key Studies
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Key Studies
Slide 31: Melbourne Dental School
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Melbourne Dental School Study showed dysplastic and cancerous tissue can be identified with InVivage® • Triage, monitor tissue health & escalate diagnosis Aim • Validate use of fluorescent probe & mouth map software Investigator • Dr Tami Yap, Professor Mi
Slide 32: University of Adelaide Oral Health Study
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Australian Research Centre for Population Oral Health at University of Adelaide Study further validates InVivage® ability to identify cancerous tissue • To assess ability of Optiscan technology to detect Aim oral squamous cell carcinoma in ex-vivo surgical
Slide 33: Australian Centre for Oral Oncology Research & Education
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Australian Centre for Oral Oncology Research & Education Study proved diagnostic decisions can be made on the fly using InVivage® • To assess ability of Optiscan technology to assist PRECANCER CANCER Aim with on-the-fly diagnosis of oral cancer and precanc
Slide 34: Breast Cancer Margin Assessment study (1/2)
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Breast Cancer Margin Assessment study (1/2) Results will unlock a new clinical application and market offering NORMAL • Determine if intraoperative imaging of excised breast Aim tissue can detect positive surgical margins pre- pathology Investigator • Prof
Slide 35: Breast Cancer Margin Assessment study (2/2)
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Breast Cancer Margin Assessment study (2/2) Extended study workflow resulting in robust correlation between images and histopathology Correlation of Optiscan images with histopathology to 1 identify healthy tissue, tumour margin and tumour. Fresh tissue im
Slide 36: The Future
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE The Future
Slide 37: Optiscan: Platform Technology
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Optiscan: Platform Technology Brain Airways ENT Esophagus Pleura Stomach Breast Small bowel Pancreas Liver Cartilage Colon Tendons Ovary Bladder Cervix Prostate 37
Slide 38: Extension Applications
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Extension Applications Almost limitless where tissue light transmittance is possible • Oral and Head & Neck • Breast • Gastrointestinal • Cervical Size of US cancer burden in 2020 Optiscan is targeting markets worth over US$62.4bn for some of the world’s m
Slide 39: Future Applications: Huge Potential
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Future Applications: Huge Potential Revolutionising Healthcare Telepathology & Remote Integration with Robotics Biopsy Channel Image-guided AI Based Identification Diagnostics Systems Compatible Devices Molecular Surgery & Diagnostics • Real-time remote •
Slide 40: Roadmap
OVERVIEW BUSINESS UPDATE KEY STUDIES FUTURE Roadmap Product Evolution Distribution Partners Clinical Studies Digital Pathology Solutions Core products Established presence and • Immediate diagnostic capability structure in Asia-Pacific • Exploring business models for • ViewnVivo® Geographic Expansio
Slide 41: Conclusion
Conclusion Global leader in digital microscopic imaging US regulatory approval submitted for oral device Internal capacity build-out undertaken Potential for indication expansion Gastrointestinal, breast, oral and cervical Scoping for strategic partnerships Telepathology, artificial intelligence
Slide 42: Thank You Questions?
Thank You Questions?
Optiscan Imaging — Shareholder Meeting (November 2022) on 6ix